Literature DB >> 24177536

Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time? A word of caution.

R Fietkau1, F Putz, G Lahmer, S Semrau, R Buslei.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24177536     DOI： 10.1007/s00066-013-0459-2

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  11 in total

1.  The role of radio- and chemotherapy in glioblastoma.

Authors:  Roger Stupp; Damien C Weber
Journal:  Onkologie       Date:  2005-06-02

2.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Authors:  Annika Malmström; Bjørn Henning Grønberg; Christine Marosi; Roger Stupp; Didier Frappaz; Henrik Schultz; Ufuk Abacioglu; Björn Tavelin; Benoit Lhermitte; Monika E Hegi; Johan Rosell; Roger Henriksson
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

3.  Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.

Authors:  Jörg Felsberg; Niklas Thon; Sabina Eigenbrod; Bettina Hentschel; Michael C Sabel; Manfred Westphal; Gabriele Schackert; Friedrich Wilhelm Kreth; Torsten Pietsch; Markus Löffler; Michael Weller; Guido Reifenberger; Jörg C Tonn
Journal:  Int J Cancer       Date:  2011-08-01       Impact factor: 7.396

4.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 5.  [Personalized neurooncology].

Authors:  M Platten; J P Steinbach; W Wick
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

6.  Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.

Authors:  Jörg Felsberg; Marion Rapp; Simon Loeser; Rolf Fimmers; Walter Stummer; Matthias Goeppert; Hans-Jacob Steiger; Britta Friedensdorf; Guido Reifenberger; Michael C Sabel
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

Authors:  Ilse Vlassenbroeck; Stéphane Califice; Annie-Claire Diserens; Eugenia Migliavacca; Josef Straub; Ivano Di Stefano; Fabrice Moreau; Marie-France Hamou; Isabelle Renard; Mauro Delorenzi; Bruno Flamion; James DiGuiseppi; Katja Bierau; Monika E Hegi
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

9.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Authors:  Wolfgang Wick; Michael Platten; Christoph Meisner; Jörg Felsberg; Ghazaleh Tabatabai; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Stephanie E Combs; Jan Vesper; Christian Braun; Jürgen Meixensberger; Ralf Ketter; Regine Mayer-Steinacker; Guido Reifenberger; Michael Weller
Journal:  Lancet Oncol       Date:  2012-05-10       Impact factor: 41.316

10.  Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM.

Authors:  Nameeta Shah; Biaoyang Lin; Zita Sibenaller; Timothy Ryken; Hwahyung Lee; Jae-Geun Yoon; Steven Rostad; Greg Foltz
Journal:  PLoS One       Date:  2011-01-07       Impact factor: 3.240
View more
  9 in total

1.  Recurrent glioblastoma: who receives tumor specific treatment and how often?

Authors:  Rieke Steffens; Sabine Semrau; Godehard Lahmer; Florian Putz; Sebastian Lettmaier; Ilker Eyüpoglu; Michael Buchfelder; Rainer Fietkau
Journal:  J Neurooncol       Date:  2016-02-23       Impact factor: 4.130

2.  Radiotherapy of spinal cord gliomas : A retrospective mono-institutional analysis.

Authors:  Stefanie Corradini; Indrawati Hadi; Vinzent Hankel; Lorenz Ertl; Ute Ganswindt; Claus Belka; Maximilian Niyazi
Journal:  Strahlenther Onkol       Date:  2015-10-30       Impact factor: 3.621

3.  Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.

Authors:  Pilar Mur; Ángel Rodríguez de Lope; Francisco Javier Díaz-Crespo; Teresa Hernández-Iglesias; Teresa Ribalta; Concepción Fiaño; Juan Fernando García; Juan Antonio Rey; Manuela Mollejo; Bárbara Meléndez
Journal:  J Neurooncol       Date:  2015-02-15       Impact factor: 4.130

4.  Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population.

Authors:  Saurabh Ray; Machaon M Bonafede; Nimish A Mohile
Journal:  Am Health Drug Benefits       Date:  2014-05

5.  The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

Authors:  Remco J Molenaar; Dagmar Verbaan; Simona Lamba; Carlo Zanon; Judith W M Jeuken; Sandra H E Boots-Sprenger; Pieter Wesseling; Theo J M Hulsebos; Dirk Troost; Angela A van Tilborg; Sieger Leenstra; W Peter Vandertop; Alberto Bardelli; Cornelis J F van Noorden; Fonnet E Bleeker
Journal:  Neuro Oncol       Date:  2014-02-06       Impact factor: 12.300

6.  Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes.

Authors:  Piernicola Pedicini; Alba Fiorentino; Vittorio Simeon; Paolo Tini; Costanza Chiumento; Luigi Pirtoli; Marco Salvatore; Giovanni Storto
Journal:  Strahlenther Onkol       Date:  2014-04-04       Impact factor: 3.621

7.  Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.

Authors:  Yvonne Rubner; Carolin Muth; Annedore Strnad; Anja Derer; Renate Sieber; Rolf Buslei; Benjamin Frey; Rainer Fietkau; Udo S Gaipl
Journal:  Radiat Oncol       Date:  2014-03-30       Impact factor: 3.481

8.  Expression of LOC285758, a Potential Long Non-coding Biomarker, is Methylation-dependent and Correlates with Glioma Malignancy Grade.

Authors:  Alenka Matjasic; Mara Popovic; Bostjan Matos; Damjan Glavac
Journal:  Radiol Oncol       Date:  2017-01-14       Impact factor: 2.991

9.  Hippocampal EUD in primarily irradiated glioblastoma patients.

Authors:  Raphael Bodensohn; Matthias Söhn; Ute Ganswindt; Gabriele Schupp; Silke B Nachbichler; Oliver Schnell; Claus Belka; Maximilian Niyazi
Journal:  Radiat Oncol       Date:  2014-12-06       Impact factor: 3.481
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.